Edition:
United States

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

1.60USD
21 Sep 2018
Change (% chg)

$0.13 (+8.84%)
Prev Close
$1.47
Open
$1.60
Day's High
$1.70
Day's Low
$1.55
Volume
15,109,329
Avg. Vol
1,001,598
52-wk High
$2.75
52-wk Low
$0.96

Chart for

About

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates... (more)

Overall

Beta: 2.63
Market Cap(Mil.): $562.41
Shares Outstanding(Mil.): 382.59
Dividend: --
Yield (%): --

Financials

  NVAX.OQ Industry Sector
P/E (TTM): -- 108.45 32.71
EPS (TTM): -0.57 -- --
ROI: -70.07 1.54 12.72
ROE: -- 0.30 14.84

BRIEF-Novavax Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

May 09 2018

BRIEF-Novavax Reports Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S

May 09 2018

BRIEF-Novavax Says Topline Efficacy Data From Prepare Phase 3 Clinical Trial Expected In Q1 Of 2019

* NOVAVAX REACHES SIGNIFICANT ENROLLMENT MILESTONE IN THE PREPARE(TM) PHASE 3 TRIAL OF ITS RSV F VACCINE

May 07 2018

BRIEF-Novavax Prices Public Offering 30.3 Mln Common Shares At $1.65 Per Share

* SAYS PUBLIC OFFERING OF 30.3 MILLION COMMON SHARES PRICED AT $1.65PER SHARE

Apr 11 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF81.88 -0.06
Merck & Co., Inc. (MRK.N) $71.10 +0.32
Sanofi SA (SASY.PA) €74.50 -0.17
GlaxoSmithKline plc (GSK.L) 1,531.40 +45.60
AstraZeneca plc (AZN.L) 5,670.00 +98.00

Earnings vs. Estimates